Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by bfwon Jun 18, 2018 2:59pm

284 Views

Post# 28187580

RE:Example of a run up on P3

Umm....are you sure the PTC data is Phase 3? It looks preliminary in nature.

RVX is far more advanced in terms of getting to market....especially after the FDA NR.

bfw

trussell09 wrote: Ptc theraputics just jumped on a positive P3. Interesting enough is the 6 month graph. It had a very nice steady climb the 6 months prior to the release. There was one drop in March because of a public offering which hammered the stock price but it recovered staedily. Would be nice to see RVX follow a similar path.

https://finance.yahoo.com/chart/PTCT

Fingers crossed.

Bullboard Posts

Options trading in a volatile macro environment